Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialJean‐Charles Soria, Tony Mok, Shinji Atagi et al.|The Lancet Oncology|2015Cited by 412
Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non–Small Cell Lung CancerIsamu Okamoto, Kazuhiko Nakagawa, Hiroshi Nokihara et al.|JAMA Oncology|2020Cited by 67
A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4–ALK Rearrangement with Resistance to the ALK Inhibitor CrizotinibNaoki Omachi, Shinji Atagi|Journal of Thoracic Oncology|2014Cited by 58
Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)Makoto Nishio, Tomohisa Kawakami, Shunichi Sugawara et al.|Clinical Lung Cancer|2019Cited by 48
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: COMPASS (WJOG5610L)Takashi Seto, Yoichi Nakanishi, Koichi Azuma et al.|Journal of Clinical Oncology|2019Cited by 43